Silodosin Capsule
Product Images NDC 46708-405

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Silodosin (NDC 46708-405). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Capsules (Silodosin 4mg)

Silodosin Capsules 4 mg per capsule oral medication label with 30 capsules per package. Label includes storage instructions, dosage information, and manufacturing details. Produced by Alembic Pharmaceuticals Limited, the label displays the NDC 46708-405-30, Alembic logo, barcode, and prescription-only designation.*

FDA Label Image

30 Capsules (Silodosin 8mg)

Label for Silodosin Capsules 8 mg by Alembic Pharmaceuticals Limited. The label indicates 8 mg strength per capsule, with a 30 capsule count. Storage instructions to keep at 25°C with allowed excursions and to protect from light and moisture are included. The label also includes usage directions and the manufacturer address in India.*

FDA Label Image

Figure 1 (Silodosin Figur1)

A line graph showing Silodosin concentration in ng/mL over time in hours. The concentration peaks around 3 to 4 hours and then gradually declines up to 24 hours. Error bars indicate variability at each time point.*

FDA Label Image

Figure 2 (Silodosin Figur2)

A line graph comparing change from baseline in IPSS Total Score over time (days) for Silodosin Capsules 8 mg versus placebo. The x-axis shows days from baseline to 84/LOCF, and the y-axis shows change in IPSS Total Score. Silodosin 8 mg shows a greater decrease from baseline compared to placebo, as depicted by distinct lines with markers for each group and statistically significant differences indicated.*

FDA Label Image

Figure 3 (Silodosin Figur3)

A line graph showing the change from baseline in IPSS Total Score over time comparing Silodosin Capsules 8 mg to placebo. The x-axis represents days (B, 3.5, 7, 14, 28, 84/LOCF), and the y-axis represents the change from baseline in IPSS total score. Silodosin shows a greater decrease in score over time compared to placebo, with significance indicated at p<0.0001.*

FDA Label Image

Figure 4 (Silodosin Figur4)

A line graph showing the change from baseline in Qmax (mL/sec) over time (days) comparing placebo and Silodosin Capsules 8 mg. The graph plots measurements at baseline, days 1, 7, 14, 28, and day 84/LOCF, indicating a greater improvement with Silodosin 8 mg compared to placebo, with markers for statistical significance (p<0.05).*

FDA Label Image

Figure 5 (Silodosin Figur5)

A line graph depicting change from baseline in Qmax (mL/sec) over days for Silodosin Capsules 8 mg compared to placebo. The graph shows values at baseline, day 1, 7, 14, 28, and 84/LOCF, with Silodosin group consistently maintaining higher Qmax values than placebo, indicating a difference over time.*

FDA Label Image

Structure (Silodosin Structure)

Chemical structure of silodosin, showing its molecular framework with aromatic rings, trifluoromethyl group, amide, and alcohol functional groups as represented in the diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.